As market demand increases the need for quick product cycles and the distribution of regulated products, the ability to react quickly to an adverse event must be considered. This trend has led to an initiative within the FDA to increase the ability to collaborate and communicate more quickly with reporting organizations. This is where MedWatch Plus comes in.
This white paper will provide an overview of the benefits and best practices of using the FDA's MedWatch Plus initiative for electronic adverse event reporting within the Pharmaceuticals industry, as well as other FDA-regulated organizations.
After completing the registration form you will have access to download the white paper.
EtQ, Inc's privacy policy